TGM4: an immunogenic prostate-restricted antigen
Abstract
Prostate cancer is the second leading cause of cancer-related death in men in the USA; death occurs when patients progress to metastatic castration-resistant prostate cancer (CRPC). Although immunotherapy with the Food and Drug Administration‐approved vaccine sipuleucel‐T, which targets prostatic acid phosphatase (PAP), extends survival for 2–4 months, the identification of new immunogenic tumor-associated antigens (TAAs) continues to be an unmet need.
Document Details
- Document Type
- Pub Defense Publication
- Publication Date
- Jun 01, 2021
- Source ID
- 10.1136/jitc-2020-001649
Entities
People
- Aleksandar Obradovic
- Alexandros Papachristodoulou
- Charles G Drake
- Emmanuel S. Antonarakis
- H. Benjamin Larman
- Jelani C. Zarif
- Laura Crowley
- Michael C. Haffner
- Michael M. Shen
- Mithil K Soni
- Patrick C. Walsh
- Pawel Muranski
- Ran Reshef
- Rodney Macedo
- Thomas R Nirschl
- Tiezheng Yuan
- Timothy O’donnell
- Uri Laserson
- Zoila A Lopez-Bujanda
Organizations
- National Cancer Institute
- National Science Foundation
- Prostate Cancer Foundation
- Swiss National Science Foundation
- United States Department of Defense